AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance

Marco Sanduzzi Zamparelli,Sergio Munoz Martinez,Mariona Calvo,Maria Varela,Neus Llarch,Gemma Iserte,Berta Laquente,Andres Castano-Garcia,Jose Luis Lledo,Christie Perello, Gemma Domenech,Ezequiel Mauro,Maria Angeles Garcia-Criado,Carmen Ayuso, Angels Kateb,Jordi Rimola,Jordi Bruix,Maria Reig

JOURNAL OF HEPATOLOGY（2023）

引用 0|浏览7
暂无评分
关键词
hepatocellular carcinoma patients,cabozantinib,hepatocellular carcinoma,sorafenib intolerance
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要